MDT

84.21

+0.41%↑

VEEV

227.67

+3.34%↑

A

106.91

+1.84%↑

WBA

11.03

+0.46%↑

CHE

546.34

-6.7%↓

MDT

84.21

+0.41%↑

VEEV

227.67

+3.34%↑

A

106.91

+1.84%↑

WBA

11.03

+0.46%↑

CHE

546.34

-6.7%↓

MDT

84.21

+0.41%↑

VEEV

227.67

+3.34%↑

A

106.91

+1.84%↑

WBA

11.03

+0.46%↑

CHE

546.34

-6.7%↓

MDT

84.21

+0.41%↑

VEEV

227.67

+3.34%↑

A

106.91

+1.84%↑

WBA

11.03

+0.46%↑

CHE

546.34

-6.7%↓

MDT

84.21

+0.41%↑

VEEV

227.67

+3.34%↑

A

106.91

+1.84%↑

WBA

11.03

+0.46%↑

CHE

546.34

-6.7%↓

Search

Allogene Therapeutics Inc

Closed

SectorHealthcare

1.56 -3.7

Overview

Share price change

24h

Current

Min

1.54

Max

1.61

Key metrics

By Trading Economics

Income

6.4M

-60M

EPS

-0.28

Employees

226

EBITDA

6.8M

-56M

Recommendations

By TipRanks

Recommendations

Strong Buy

12 Months Forecast

+434.59% upside

Dividends

By Dow Jones

Next Earnings

12 maj 2025

Market Stats

By TradingEconomics

Market Cap

-149M

309M

Previous open

5.26

Previous close

1.56

Technical Score

By Trading Central

Confidence

Very Strong Bullish Evidence

Allogene Therapeutics Inc Chart

Wyniki osiągnięte w przeszłości nie są gwarantem przyszłych wyników.

Related News

24 kwi 2025, 23:54 UTC

Hot Stocks

Stocks to Watch: Alphabet, Intel, AppFolio

24 kwi 2025, 23:51 UTC

Market Talk

Gold Edges Higher, Supported by U.S. Dollar Weakness -- Market Talk

24 kwi 2025, 23:46 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

24 kwi 2025, 23:46 UTC

Market Talk

Nikkei May Rise on Hopes for Easing U.S.-China Trade Tensions -- Market Talk

24 kwi 2025, 23:37 UTC

Top News

Big Tech Braces for Tariff-Induced Advertising Slowdown -- WSJ

24 kwi 2025, 23:36 UTC

Top News

Tokyo Consumer Inflation Accelerates in April as Companies Raise Prices

24 kwi 2025, 23:13 UTC

Top News
Earnings

Google's Earnings Power Holds Up in Global Turbulence -- Update

24 kwi 2025, 23:09 UTC

Top News

Trump Initiatives Knocked Back in a New Round of Court Rulings -- 2nd Update

24 kwi 2025, 23:02 UTC

Acquisitions, Mergers, Takeovers

SK Telecom to Sell 10.8M Kakao Shares via After-Hours Block Trading

24 kwi 2025, 23:02 UTC

Acquisitions, Mergers, Takeovers

SK Telecom to Dispose of 2.4% Stake in Kakao to Raise KRW413.27B

24 kwi 2025, 22:51 UTC

Top News
Acquisitions, Mergers, Takeovers

Germany's Merck Nears Roughly $3.5 Billion Deal for SpringWorks -- Update

24 kwi 2025, 22:48 UTC

Top News

Walmart Walks the DEI Tightrope in Latest Proxy Statement -- Barrons.com

24 kwi 2025, 22:47 UTC

Market Talk

Intel Remains in Tough Position, CFRA Research Analyst Says -- Market Talk

24 kwi 2025, 22:38 UTC

Market Talk
Earnings

Tariffs Hurt Intel's 2Q Outlook as CFO Warns Economic Slowdown is Likely -- Market Talk

24 kwi 2025, 22:24 UTC

Earnings

Aluminum Corp. of China: Increase in Product Sales Supported 1Q Results >2600.HK

24 kwi 2025, 22:24 UTC

Earnings

Aluminum Corp. of China 1Q Rev CNY55.78B Vs. CNY48.96B >2600.HK

24 kwi 2025, 22:24 UTC

Market Talk
Earnings

Intel's Comeback Involves More Engineers, More In-Office Work -- Market Talk

24 kwi 2025, 22:23 UTC

Earnings

Aluminum Corp. of China 1Q Net CNY3.54B Vs. Net CNY2.23B >2600.HK

24 kwi 2025, 22:11 UTC

Market Talk
Earnings

Global Equities Roundup: Market Talk

24 kwi 2025, 22:11 UTC

Market Talk
Earnings

Intel CEO: Layoffs Will Simplify Company Structure -- Market Talk

24 kwi 2025, 22:09 UTC

Top News
Earnings

Intel Cuts Outlook, Says Layoffs Are in Store -- Update

24 kwi 2025, 22:00 UTC

Market Talk
Earnings

T-Mobile's Key Subscriber Metric Disappoints Despite Earnings Beat -- Market Talk

24 kwi 2025, 21:39 UTC

Top News

Trump Initiatives Knocked Back in a New Round of Court Rulings -- WSJ

24 kwi 2025, 21:24 UTC

Earnings

Bristol Myers Reports Better-Than-Expected Earnings. The Future Is Cloudy. -- Barrons.com

24 kwi 2025, 21:24 UTC

Top News
Earnings

Google's Earnings Power Holds Up in Global Turbulence -- WSJ

24 kwi 2025, 21:23 UTC

Top News
Earnings

Intel Cuts Outlook, Says Layoffs Are in Store -- WSJ

24 kwi 2025, 21:04 UTC

Earnings

T-Mobile Reports Strong Earnings but Its Wireless Results Disappoint. The Stock Is Sliding. -- Barrons.com

24 kwi 2025, 21:03 UTC

Earnings

Agnico-Eagle Mines Believes Its Rev Structure Will Be Largely Unaffected by the Tariffs >AEM.T

24 kwi 2025, 21:03 UTC

Earnings

Agnico-Eagle Mines Total Expected Capex for 2025 Still Estimated at $1.75 B to $1.95 B >AEM.T

24 kwi 2025, 21:02 UTC

Earnings

Agnico-Eagle Mines Positioned to Achieve 2025 AISC Per Ounce Guidance of $1,250 to $1,300. >AEM.T

Peer Comparison

Price change

Allogene Therapeutics Inc Forecast

Price Target

By TipRanks

434.59% upside

12 Months Forecast

Average 8.5 USD  434.59%

High 14 USD

Low 4 USD

Based on 12 Wall Street analysts offering 12 month price targets forAllogene Therapeutics Inc - Dist in the last 3 months.

Rating Consensus

By TipRanks

Strong Buy

12 ratings

11

Buy

1

Hold

0

Sell

Technical Score

By Trading Central

1.42 / N/ASupport & Resistance

Short Term

Very Strong Bullish Evidence

Intermediate Term

Weak Bullish Evidence

Long Term

Bearish Evidence

Financials

Selling and administration expenses

Operating expenses

Pre-tax profit

Sales

Cost of sales

Gross profit on sales

Interest expense on debt

EBITDA

Operating profit

$

About Allogene Therapeutics Inc

Allogene Therapeutics, Inc., a clinical stage immuno-oncology company, develops and commercializes genetically engineered allogeneic T cell therapies for the treatment of cancer. It develops, manufactures, and commercializes UCART19, an allogeneic chimeric antigen receptor (CAR) T cell product candidate for the treatment of pediatric and adult patients with R/R CD19 positive B-cell acute lymphoblastic leukemia (ALL). The company also develops cemacabtagene ansegedleucel, an engineered allogeneic CAR T cell product candidate that targets CD19 for the treatment of large B-cell lymphoma; and is in Phase 1b clinical trial for the treatment of chronic lymphocytic leukemia. In addition, it is developing ALLO-715, an allogeneic CAR T cell product candidate that is in a Phase 1 clinical trial for treating R/R multiple myeloma; ALLO-605, an allogeneic CAR T cell product candidate that is in a Phase I clinical trial for the treatment of multiple myeloma; ALLO-647, an anti-CD52 monoclonal antibody; CD70 to treat renal cell cancer; ALLO-316, an allogeneic CAR T cell product candidate that is in Phase 1 clinical trial for the treatment of advanced or metastatic RCC; ALLO-329 for the treatment of certain autoimmune diseases; DLL3 for the treatment of small cell lung cancer and other aggressive neuroendocrine tumors; and Claudin 18.2 for the treatment of gastric and pancreatic cancer. The company has license and collaboration agreements with Pfizer Inc.; Servier; Cellectis S.A.; and Notch Therapeutics Inc. It also has a strategic collaboration agreement with The University of Texas MD Anderson Cancer Center for the preclinical and clinical investigation of allogeneic CAR T cell product candidates; and a strategic partnership with Foresight Diagnostics to develop MRD-based In-Vitro Diagnostic for use in ALPHA3. The company was incorporated in 2017 and is headquartered in South San Francisco, California.